A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens (Q38944133)

7 September 2017

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens (English)

1 reference

7 September 2017

0 references

3

Kara S Cox

1 reference

7 September 2017

1

Gokul Swaminathan

1 reference

7 September 2017

Elizabeth A Thoryk

2

1 reference

7 September 2017

Steven Meschino

4

1 reference

7 September 2017

Sheri A Dubey

5

1 reference

7 September 2017

Kalpit A Vora

6

1 reference

7 September 2017

Robert Celano

7

1 reference

7 September 2017

Marian Gindy

8

1 reference

7 September 2017

Danilo R Casimiro

9

1 reference

7 September 2017

Andrew J Bett

10

1 reference

7 September 2017

language of work or name

English

0 references

publication date

7 November 2015

1 reference

7 September 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

7 September 2017

34

1 reference

7 September 2017

1

1 reference

7 September 2017

110-119

1 reference

Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Advances in aluminum hydroxide-based adjuvant research and its mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Intracellular detection of viral nucleic acids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Accessing the therapeutic potential of immunostimulatory nucleic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Adjuvant activity of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

CpG oligodeoxynucleotides as mucosal adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Rationally-designed vaccine adjuvants: separating efficacy from toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Rational design of small molecules as vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Key roles of adjuvants in modern vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

The path to a successful vaccine adjuvant--'the long and winding road'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Vaccine delivery using nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Targeted immunomodulation using antigen-conjugated nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Lipid-based nanoparticles in the systemic delivery of siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Lymphokine control of in vivo immunoglobulin isotype selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Innate immune response in Th1- and Th2-dominant mouse strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Cellular interactions of therapeutically delivered nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Influences of excipients on in vitro release and in vivo performance of tetanus toxoid loaded polymer particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Phenotype and function of protective, CD4-independent CD8 T cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Cationic liposomes as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Cationic lipids activate intracellular signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.10.132

10.1016/J.VACCINE.2015.10.132

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference